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Background:  Myostatin (MSTN) is a negative regulator of muscle growth that may improve insulin sensitivity. We hypothesized that MSTN 
inhibition would improve cardiomyocyte glucose metabolism in high fat diet-induced obesity.
methods:  C57BL/6J mice were fed ad libitum with standard chow (control, n=9) or with high fat diet (FD) (n=20) for 8 weeks. FD mice 
were treated with a MSTN inhibitor (Myo-I, weekly 12µg/kg) or vehicle for the duration of the experiment. Myo-I is a MSTN neutralizing 
antibody that inhibits MSTN signaling. After treatment, glucose tolerance test was performed and mice were sacrificed.
results:  Treatment with Myo-I resulted in significant attenuation of body weight gain and glucose intolerance in FD mice. Circulating 
serum MSTN was significantly increased in FD mice and reduced after Myo-I therapy, while cardiac MSTN remained unchanged. However, 
increased cardiac MSTN signaling, as reflected by P-SMAD2,3, was confirmed in FD mice and was prevented by Myo-I. Abnormal cardiac 
glucose regulation was evident as shown by significantly reduced cardiac P-AMPK/AMPK and GLUT4 and increased P-AKT/AKT. In 
contrast, MSTN inhibition normalized cardiac AMPK, GLUT4 and AKT in FD mice.
conclusion:  Abnormal glucose metabolism with dysregulation of MSTN is present in high fat diet-induced obesity, and MSTN inhibition 
may improve cardiac glucose handling by altering AMPK and GLUT4. MSTN inhibition may have important implications for insulin 
resistance therapy and cardiovascular health in obesity.
Table 1. Serum and cardiac protein changes in FD Mice
Control
(n=9)
FD + vehicle
(n=10) FD + Myo-I (n=9)
Body weight (g) 29.3 2 ± 0.9 38.0 ± 1.0* 33.8 ± 1.3*#
Glucose tolerance test peak (mg/dl) 308 ± 14 512 ± 25* 445 ± 26*#
Serum MSTN (pg/ml) 33,939 ± 2949 67,923 ± 723* 45,194 ± 13089*#
Cardiac MSTN 100 ± 2 119 ± 2 105 ± 3
Cardiac P-SMAD2/3
/SMAD 2/3 100 ± 3 124 ± 3* 94 ± 2#
Cardiac P-AMPK /AMPK 100 ± 2 62 ± 2* 109 ± 2#
Cardiac GLUT4 100 ± 1 55 ± 2* 88 ± 1*#
Cardiac P-AKT/AKT 100 ± 8 126.8 ± 3* 87.8 ± 6#
FD = high fat diet, *p<0.05 vs. control, #p<0.05 vs. FD+vehicle
